Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $477.96 Average PT from Analysts

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-eight ratings firms that are covering the company, Marketbeat reports. Five research analysts have rated the stock with a hold recommendation, twenty-two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $477.9604.

A number of equities analysts have weighed in on ALNY shares. Freedom Capital raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 17th. Chardan Capital cut their price target on Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating on the stock in a research note on Friday, February 13th. Oppenheimer initiated coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price objective for the company. Stifel Nicolaus lifted their price objective on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Finally, Bank of America reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th.

Insiders Place Their Bets

In other news, EVP Jeffrey V. Poulton sold 2,206 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $722,795.90. Following the completion of the sale, the executive vice president owned 64,273 shares of the company’s stock, valued at approximately $21,059,048.45. The trade was a 3.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $319.73, for a total transaction of $528,193.96. Following the completion of the sale, the executive vice president directly owned 21,860 shares of the company’s stock, valued at $6,989,297.80. The trade was a 7.03% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 53,923 shares of company stock valued at $18,072,087. 1.50% of the stock is owned by insiders.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Hsbc Holdings PLC grew its position in shares of Alnylam Pharmaceuticals by 22.6% in the 4th quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock worth $35,675,000 after acquiring an additional 16,503 shares in the last quarter. SHP Wealth Management bought a new position in Alnylam Pharmaceuticals during the fourth quarter worth $43,000. Reflection Asset Management acquired a new position in Alnylam Pharmaceuticals in the fourth quarter worth $63,000. Wick Capital Partners LLC acquired a new position in Alnylam Pharmaceuticals in the fourth quarter worth $306,000. Finally, Alpine Global Management LLC bought a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at $820,000. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Stock Down 0.0%

Shares of ALNY traded down $0.12 during mid-day trading on Friday, reaching $317.11. 70,207 shares of the stock traded hands, compared to its average volume of 1,405,799. The stock has a fifty day simple moving average of $346.09 and a 200 day simple moving average of $410.94. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $495.55. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. The firm has a market cap of $42.05 billion, a price-to-earnings ratio of 185.20 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The firm had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same quarter last year, the company posted ($0.65) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 84.9% compared to the same quarter last year. Sell-side analysts expect that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.